Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 14/20 | 0.35 |
| ▸ | NR1H3 | Q13133 | 14/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 7/20 | 0.32 |
| ▸ | PPARA | Q07869 | 6/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 5/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116955 | 0.89 | ACHE (0.37) | ACHETLR9TLR8TLR7BCHE | |
| SCHEMBL4115043 | 0.88 | GRM2 (0.38) | ACHENR1H2NR1H3TLR9TLR8 | |
| SCHEMBL13596019 | 0.87 | ACHE (0.45) | ACHETLR9TLR8TLR7BCHE | |
| SCHEMBL4132429 | 0.87 | ACHE (0.36) | ACHENR1H2NR1H3TLR9TLR8 | |
| SCHEMBL4114643 | 0.85 | SLC6A4 (0.41) | ACHETLR9TLR8TLR7BCHE | |
| SCHEMBL4121186 | 0.85 | ACHE (0.44) | ACHEBCHE | |
| SCHEMBL4131030 | 0.85 | ACHE (0.41) | ACHENR1H2NR1H3PPARDPPARA | |
| SCHEMBL4121137 | 0.84 | ACHE (0.44) | ACHENR1H2NR1H3PPARDPPARA | |
| SCHEMBL4120695 | 0.84 | ACHE (0.35) | ACHETLR9TLR8TLR7BCHE | |
| SCHEMBL4120701 | 0.84 | ACHE (0.35) | ACHETLR9TLR8TLR7BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318690-A1 | Benzisoxazole Compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2017275-A1 | BENZISOXAZOLE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318690-A1 | Benzisoxazole Compound | NR1I2, NR1I3, NR0B1 | ACHE 3716/4885NR1H2 45/4885NR1H3 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.